Gene and cell therapy using cell fusion technology
AssigneeCuramys Inc.
InventorsJung-Joon SUNG, Seung-Yong SEONG, Hee-Woo LEE, Ki Yoon KIM
Life of this patent
Estimating the term…
Abstract
A gene and cell therapy using a cell fusion technology is proposed. Cells overexpressing hemagglutinin neuraminidase (HN) and fusion (F) proteins have effects of enhancing cell fusion with other cells, restoring cell damage through the cell fusion with damaged cells, and transferring a normal gene. Therefore, when a vector including genes encoding the HN and F proteins of the present invention or a cell transformed with the vector is clinically applied to neurodegenerative diseases, muscular diseases, and the like, an effect of reducing the damage of damaged cells through cell fusion can be expected.
Claims8
A method for reducing nerve cell damage, comprising:
- administering stem cells or progenitor cells transformed with a vector including genes encoding hemagglutinin neuraminidase (HN) and fusion (F) proteins to a subject with a therapeutically effective dose,
- wherein the subject suffers from neurodegenerative diseases having nerve cell damage or neurological diseases having nerve cell damage.
A method for treating neurodegenerative diseases having nerve cell damage or neurological diseases having nerve cell damage, comprising:
- administering stem cells or progenitor cells transformed with a vector including genes encoding hemagglutinin neuraminidase (HN) and fusion (F) proteins to a subject with a therapeutically effective dose,
- wherein the subject suffers from neurodegenerative diseases having nerve cell damage or neurological diseases having nerve cell damage.
Dependencies are inferred from the claim text.